Register | Login
World Pharma News .net


Given the concerns over how widely marketed Vytorin and Zetia were over the past few years, the FDA response to Genzyme and Isis raises an interesting thought - whether the agency is no longer willing to approve new drugs for wide use based solely on the ability to improve cholesterol. What do you think?

Who Voted for this Story



Enter your email address:

Delivered by FeedBurner